Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.
Looking for a particular Endocyte employee's phone or email?
The Endocyte annual revenue was $32.52 million in 2026.
Patrick Klein is the Director of Toxicology of Endocyte.
8 people are employed at Endocyte.
Endocyte is based in West Lafayette, Indiana.
The NAICS codes for Endocyte are [32541, 325412, 325, 32, 3254].
The SIC codes for Endocyte are [28, 283].